Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or Pantoprazole

PHASE4RecruitingINTERVENTIONAL

Enrollment

128

Participants

Timeline

Start Date

July 30, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

Gastroesophageal Reflux Disease

Interventions

DRUG

Tegoprazan

Tegoprazan 50 mg daily for 28 days

DRUG

Pantoprazole

Pantoprazole 40 mg daily for 28 days

Trial Locations (2)

RECRUITING

Saluz Investigación, S.C., Boca del Río

RECRUITING

Gastrologen S.A. de C.V., Mexico City